Table 4 In vitro susceptibility to various antifungal agents of selected Candida species causing invasive candidiasis in neonatal versus non-neonatal pediatric patients
|  | All Candida (total n = 295) | C. albicans | C. parapsilosis | Other Candida spp. | |||||
|---|---|---|---|---|---|---|---|---|---|
All episodes | Neonates | Children | Neonates | Children | Neonates | Children | Neonates | Children | |
Fluconazole | |||||||||
 Susceptible | 251 (85.1) | 87 (83.7) | 164 (85.9) | 47 (97.9) | 73 (94.8) | 30 (100) | 59 (100) | 10 (38.5) | 32 (58.2) |
 S-DD or R | 44 (17.5) | 17 (16.3) | 27 (14.1) | 1 (2.1) | 4 (5.2) | 0 (0) | 0 (0) | 16 (61.5) | 23 (41.8) |
Voriconazole | |||||||||
 Susceptible | 262 (88.8) | 97 (93.3) | 165 (86.4) | 47 (97.9) | 73 (94.8) | 30 (100) | 59 (100) | 20 (76.9) | 33 (60) |
 S-DD or R | 33 (11.2) | 7 (6.7) | 26 (13.6) | 1 (2.1) | 4 (5.2) | 0 (0) | 0 (0) | 6 (23.1) | 22 (40) |
Amphotericin B | |||||||||
 Susceptible | 292 (99.0) | 104 (100) | 188 (64.6) | 48 (100) | 77 (100) | 30 (100) | 59 (100) | 26 (100) | 52 (94.5) |
 S-DD or R | 3 (1.0) | 0 (0) | 3 (1.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (5.5) |
Micafungin | |||||||||
 Susceptible | 291 (98.6) | 102 (98.1) | 189 (99.0) | 48 (100) | 76 (98.7) | 28 (93.3) | 58 (98.3) | 26 (100) | 55 (100) |
 S-DD or R | 4 (1.4) | 2 (1.9) | 2 (1.0) | 0 (0) | 1 (1.3) | 2 (6.7) | 1 (1.7) | 0 (0) | 0 (0) |
Caspofungin | |||||||||
 Susceptible | 293 (99.3) | 104 (100) | 189 (99.0) | 48 (100) | 77 (100) | 30 (100) | 59 (100) | 26 (100) | 53 (96.4) |
 S-DD or R | 2 (0.7) | 0 (0) | 2 (1.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (3.6) |